YOU ARE HERE: LAT HomeCollectionsCloning


November 7, 2008 | Thomas H. Maugh II, Maugh is a Times staff writer.
Robert H. Foote, the Cornell University researcher who pioneered the study of DNA synthesis in the testes, in vitro fertilization and other aspects of reproduction and who was the last surviving officer of World War II's famed "Go for Broke" 442nd Regimental Combat Team composed of Japanese Americans, died of lung failure in Ithaca, N.Y., on Oct. 27. He was 86.
October 7, 2008 | From the Associated Press
Eli Lilly & Co.'s winning bid of more than $6 billion for cancer drug maker ImClone Systems Inc. means a billion-dollar payday for former rival bidder Bristol-Myers Squibb Co. and vindication for corporate raider and ImClone Chairman Carl Icahn. Lilly said Monday that it would pay $70 a share for New York-based ImClone.
October 3, 2008 | Robert Lloyd, Times Television Critic
I'm one of those who thinks that with regards to the "Star Wars" saga, it's all been mostly downhill since "The Empire Strikes Back," except, of course, Carrie Fisher in slave gear for "Return of the Jedi." You may go ahead and hate me now, people under 30, you for whom Anakin Skywalker constitutes an interesting character, or simply take it as evidence that I am old and do not know what I am saying.
October 2, 2008 | From Bloomberg News
ImClone Systems Inc., the cancer drug maker controlled by billionaire Carl Icahn, said Wednesday that a pharmaceutical company had proposed acquiring it in a deal that was not subject to financing or further due diligence. The prospective buyer requested its name not be divulged yet, ImClone said. Earlier, the Wall Street Journal reported that Eli Lilly & Co. was in talks with ImClone. Lilly, based in Indianapolis, is facing generic competition to its $1.
September 11, 2008 | From the Associated Press
Biotechnology company ImClone Systems Inc. said Wednesday that it was considering a buyout offer worth $70 a share from an unidentified large pharmaceutical company, and it rejected a $60-per-share bid from partner Bristol-Myers Squibb Co. ImClone said Chairman Carl Icahn has been in talks with the chief executive of the pharmaceutical company that made the new offer, which would be worth about $6.1 billion. ImClone's board will allow the potential buyer two weeks to do due diligence.
August 15, 2008 | Michael Ordona, Special to The Times
With, presumably, no more live-action episodes coming, what can fans reasonably expect from "Star Wars: The Clone Wars," the theatrical pilot for the upcoming animated television series? Well, there's knockout animation, facsimiles of popular characters and plenty of action. But anyone older than 8 with the majority of brain functions intact will have a bad feeling about this.
August 14, 2008 | Geoff Boucher, Times Staff Writer
George LUCAS, looking overheated under the midday sun, gamely worked the red carpet last Sunday at the world premiere of the latest cinematic installment to his space saga, "Star Wars: The Clone Wars." At one point, Lucas was photographed with one of his most avid fans, a grinning, chubby fellow from Pennsylvania who showed up at Hollywood's Egyptian Theatre wearing two-day stubble, a sweat-stained shirt and a brimmed frontier hat that Indiana Jones would admire.
August 5, 2008 | From the Associated Press
ImClone Systems Inc.'s board of directors said Monday that cancer drug partner Bristol-Myers Squibb Co.'s $4.5-billion buyout offer "substantially undervalues" the company, with Chairman Carl Icahn personally against the deal. Despite calling the bid too low, ImClone stopped short of rejecting it and said its board formed a committee to weigh the offer. The board also said it was considering splitting the company into two units to focus on Erbitux and its developing pipeline separately.
August 1, 2008 | From the Associated Press
Bristol-Myers Squibb Co. on Thursday offered $4.5 billion in cash for biotechnology company ImClone Systems Inc., saying the two, which are cancer drug partners, were "a natural fit." The proposal offers ImClone stockholders $60 a share, a 30% premium over the company's closing price of $46.44 on Wednesday. Bristol-Myers, the world's No. 14 drug maker by revenue, already owns about 17% of ImClone.
Los Angeles Times Articles